2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2608

Time in Remission Is Important for Improvement of Physical Function in Patients with Rheumatoid Arthritis (RA)
Abstract Number: 2481

Time Trends in Corticosteroid Use in Rheumatoid Arthritis: Results From a Population Based Inception Cohort 1980–1994 Vs. 1995–2007
Abstract Number: 112

Time-Integrated Synovitis Activity Assessed by Power Doppler Ultrasound Significantly Correlates with Radiographic Progression in Rheumatoid Arthritis Patients Treated with Methotrexate Alone but Not in Those Treated with TNF Antagonists
Abstract Number: 2641

Time-to-Improvement of Pain and Sleep in Clinical Trials of Pregabalin Treatment of Fibromyalgia
Abstract Number: 48

Tissue Engineering for Articular Cartilage Repair, Culturing Bone Marrow Mesenchymal Stem Cells On Collagen and Heparan Sulphate Scaffolds
Abstract Number: 2467

Tissue Lesions in Osteoarthritis Initiative Participants with Normal X-Rays and Risk Factors for Incident Cartilage Damage
Abstract Number: 2353

TLR2 Activation by Acute Serum Amyloid A Induces Pro-Inflammatory Mechanisms in a Novel Ex Vivo Temporal Artery Explant Culture/Model of Giant Cell Arteritis
Abstract Number: 1074

TLR2 Deletion Promotes Arthritis and Joint Destruction Through Reduction of IL-10
Abstract Number: 508

TLR3-Signaling Induces the Expression of Ro/SSA and La/SSB Autoantigens in Salivary Gland Epithelial Cells (SGECs)
Abstract Number: 2669

TLR7 Ligation Contributes to Monocyte Migration in Rheumatoid Arthritis
Abstract Number: 1517

TLR9 Signaling in Fibroblasts Promotes Pro-Fibrotic Responses Via TGF-Beta
Abstract Number: 501

TNF Inhibitor Treatment in Rheumatoid Arthritis (RA) Patients with Moderate Versus High Disease Activity At Baseline: A Comparison of Utility Gains, Response and Remission Rates
Abstract Number: 1804

TNF-Like Protein 1A/Death Receptor 3 Pathway Regulates Osteoclastogenesis and Is Associated with Erosive Disease in Rheumatoid Arthritis
Abstract Number: 874

TNFα Induces Sustained Signaling and a Prolonged and Unremitting Inflammatory Response in Synovial Fibroblasts
Abstract Number: 1783

TNFα Influences RasGRP1 and RasGRP3 Expression Levels in PBMC, B and T Cells

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].